CureGene's CG-0416 Shows Superior Fat Loss While Preserving Muscle in Preclinical Obesity Studies
核心洞察
CureGene (搜索) presented preclinical data for CG-0416, a novel oral thyroid hormone receptor beta agonist that achieved 95% fat mass reduction with minimal muscle loss in obese mouse models.
The compound demonstrated synergistic effects when combined with GLP-1 receptor agonists, increasing weight loss from 24% to 40% while mitigating muscle loss associated with GLP-1 monotherapy.
CG-0416 operates through a peripheral liver metabolism mechanism that avoids GLP-1-associated gastrointestinal side effects and psychiatric effects linked to appetite suppression.
CureGene (搜索) Pharmaceuticals unveiled groundbreaking preclinical data for CG-0416, a novel oral non-GLP-1 weight-loss therapy, at Obesity Week 2025 in Atlanta. The highly liver-targeted thyroid hormone receptor beta (THR-β (搜索)) agonist demonstrated superior "high-quality weight loss" by reducing fat mass while preserving muscle tissue, positioning it as a potential paradigm shift in obesity treatment beyond current GLP-1-based therapies.
Addressing GLP-1 Limitations Through Novel Mechanism
While GLP-1 receptor agonists like semaglutide have shown significant efficacy, they present core challenges including muscle loss, gastrointestinal side effects, and injectable administration requirements. CG-0416 addresses these limitations through a distinct peripheral mechanism that precisely activates the THR-β (搜索) receptor in the liver, directly boosting hepatic metabolism to promote fat burning and energy expenditure without acting on the central appetite control system.
This peripheral approach fundamentally avoids potential psychiatric effects and gastrointestinal adverse events associated with potent appetite suppression while effectively protecting muscle tissue.
Superior Fat-to-Muscle Loss Ratio in Preclinical Studies
In diet-induced obese mouse models, CG-0416 monotherapy demonstrated remarkable body composition improvements. While achieving weight reduction comparable to semaglutide, approximately 95% of the weight loss with CG-0416 came from fat mass reduction, with minimal muscle loss. In contrast, about one-third of semaglutide-induced weight loss was attributed to lean mass reduction.
The compound also significantly reduced blood and liver lipid levels and improved glucose tolerance, offering comprehensive metabolic benefits. By not strongly suppressing appetite, CG-0416 is expected to significantly reduce nausea, vomiting, and other gastrointestinal adverse events, potentially leading to better patient adherence.
Synergistic Combination Effects
The studies explored combination therapies of CG-0416 with various GLP-1 receptor agonists, revealing powerful synergistic effects. When combined with semaglutide, the therapy increased weight loss from 24% (semaglutide monotherapy) to 40%, with some obese mice returning to a healthy weight range. The combination also significantly mitigated muscle loss associated with GLP-1 receptor agonist monotherapy, increasing body muscle percentage.
Similar synergistic effects were observed when CG-0416 was combined with oral orforglipron, confirming the robustness of this dual-pathway approach. This innovative strategy combines central appetite regulation through GLP-1 receptor agonists with peripheral liver metabolism activation via CG-0416.
Clinical Applications and Patient Populations
As a once-daily oral agent, CG-0416 enhances convenience and patient compliance compared to injectable alternatives. The therapy addresses diverse patient needs through two potential applications:
Monotherapy: Ideal for individuals seeking fat loss with muscle preservation and for patients intolerant to GLP-1-based therapies.
Combination therapy: Provides a more potent, higher-quality treatment option with reduced muscle loss for patients with obesity and metabolic syndrome requiring profound weight loss and metabolic restoration.
Technology Platform Validation
The data validate the efficiency of CureGene (搜索)'s "Jade" prodrug technology platform. Founded in 2018 and headquartered in China, CureGene is a clinical-stage biotech company with a diversified pipeline of first-in-class candidates targeting cardio-cerebrovascular disorders, antiviral therapies, and metabolic dysregulation.
CG-0416 represents what the company positions as a critical step toward high-quality, sustainable, and personalized weight management, moving beyond merely supplementing existing treatments to establishing a new therapeutic paradigm in obesity care.